The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2021 | 1st FLOR: nivolumab and rituximab in follicular lymphoma
Eliza A. Hawkes, MBBS Hons, FRACP, DMedSc, Olivia Newton-John Cancer Centre, Melbourne, Australia, summarizes the findings from the Phase II 1st FLOR study (NCT03245021), which assessed nivolumab and rituximab in patients with follicular lymphoma. Initial treatment with nivolumab alone and subsequent treatment with nivolumab and rituximab served the purpose of priming the immune system for tumor-directed therapy. Current treatment regimens involve chemoimmunotherapy or rituximab and lenalidomide, which may have high toxicity. Nivolumab and rituximab resulted in a satisfactory toxicity profile with no treatment-related deaths and a high response rate. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
